BidaskClub Downgrades Regeneron Pharmaceuticals (REGN) to Strong Sell

BidaskClub cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a sell rating to a strong sell rating in a research report released on Thursday morning, BidAskClub reports.

REGN has been the subject of several other reports. Guggenheim cut shares of Regeneron Pharmaceuticals from a buy rating to a neutral rating and lowered their price objective for the company from $466.00 to $425.00 in a research note on Friday, February 22nd. TheStreet raised shares of Regeneron Pharmaceuticals from a c+ rating to a b rating in a research report on Thursday, January 17th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and set a $472.00 price target for the company in a research report on Thursday, February 7th. Cowen reaffirmed a hold rating and set a $385.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, January 7th. Finally, Piper Jaffray Companies upped their price target on shares of Regeneron Pharmaceuticals to $487.00 and gave the stock an overweight rating in a research report on Tuesday, February 26th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $413.94.

Shares of NASDAQ REGN traded down $6.33 during trading on Thursday, hitting $343.66. 845,502 shares of the company traded hands, compared to its average volume of 841,326. Regeneron Pharmaceuticals has a 1 year low of $281.89 and a 1 year high of $442.00. The stock has a market capitalization of $37.55 billion, a PE ratio of 17.36, a P/E/G ratio of 1.33 and a beta of 1.18. The company has a quick ratio of 3.67, a current ratio of 4.47 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.73 billion. During the same period in the previous year, the company earned $5.23 EPS. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals will post 19.92 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a document filed with the SEC, which is available at this link. 12.42% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. Whittier Trust Co. lifted its holdings in Regeneron Pharmaceuticals by 195.7% in the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 45 shares in the last quarter. Rehmann Capital Advisory Group lifted its holdings in Regeneron Pharmaceuticals by 1,700.0% in the 3rd quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 68 shares in the last quarter. AdvisorNet Financial Inc lifted its holdings in Regeneron Pharmaceuticals by 208.0% in the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 52 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth $29,000. Finally, Captrust Financial Advisors acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth $30,000. Hedge funds and other institutional investors own 67.04% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: How does a 12b-1 fee affect fund performance?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.